http://www.unboundmedicine.com/medline/ebm/research/fosamprenavir_calciumUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/19907722/full_citation/Gateways_to_clinical_trials_Tomillero A, Moral MA 
Gateways to clinical trials. [Journal Article]
Methods Find Exp Clin Pharmacol 2009 Sep; 31(7):463-93.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19863619/full_citation/Steady_state_amprenavir_and_tenofovir_pharmacokinetics_after_coadministration_of_unboosted_or_ritonavir_boosted_fosamprenavir_with_tenofovir_disoproxil_fumarate_in_healthy_volunteers_Luber A, Condoluci D, Slowinski P, et al. 
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. [JOURNAL ARTICLE]
HIV Med 2009 Oct 23.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19785663/full_citation/Effects_of_nucleoside_reverse_transcriptase_inhibitor_backbone_on_the_efficacy_of_first_line_boosted_highly_active_antiretroviral_therapy_based_on_protease_inhibitors:_meta_regression_analysis_of_12_clinical_trials_in_5168_patients_Hill A, Sawyer W 
Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. [Journal Article]
HIV Med 2009 Oct; 10(9):527-35.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19714702/full_citation/The_history_of_antiretrovirals:_key_discoveries_over_the_past_25_years_De Clercq E 
The history of antiretrovirals: key discoveries over the past 25 years. [JOURNAL ARTICLE]
Rev Med Virol 2009 Aug 27; 19(5):287-299.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19697398/full_citation/A_comparison_of_HIV_1_drug_susceptibility_as_provided_by_conventional_phenotyping_and_by_a_phenotype_prediction_tool_based_on_viral_genotype_Van Houtte M, Picchio G, Van Der Borght K, et al. 
A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype. [JOURNAL ARTICLE]
J Med Virol 2009 Aug 20; 81(10):1702-1709.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19681945/full_citation/Fosamprenavir_treatment_in_a_highly_active_antiretroviral_therapy_schedule_induces_a_HCV_RNA_decrease_and_a_Th1_network_boost_in_HIV/HCV_coinfected_patients_Perrella A, Sbreglia C, D'Antonio A, et al. 
Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients. [JOURNAL ARTICLE]
Clin Microbiol Infect 2009 Jul 20.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19667283/full_citation/Pharmacokinetics_of_Fosamprenavir_plus_Ritonavir_in_HIV_1_infected_Adult_Subjects_with_Hepatic_Impairment_Perez-Elias MJ, Larrousse Morellon M, Ortega E, et al. 
Pharmacokinetics of Fosamprenavir plus Ritonavir in HIV-1-infected Adult Subjects with Hepatic Impairment. [JOURNAL ARTICLE]
Antimicrob Agents Chemother 2009 Aug 10.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19637947/full_citation/Pharmacokinetics_of_concurrent_administration_of_fosamprenavir_and_atazanavir_without_ritonavir_in_human_immunodeficiency_virus_negative_subjects_McRae M, Clay PG, Anderson PL, et al. 
Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects. [Journal Article, Research Support, Non-U.S. Gov't]
Pharmacotherapy 2009 Aug; 29(8):937-42.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19632955/full_citation/Steady_State_Amprenavir_Tenofovir_and_Emtricitabine_Pharmacokinetics_Before_and_After_Reducing_Ritonavir_Boosting_of_a_Fosamprenavir/Tenofovir/Emtricitabine_Regimen_from_200_mg_to_100_mg_Once_Daily__TELEX_II__Parks DA, Jennings HC, Taylor C, et al. 
Steady-State Amprenavir, Tenofovir, and Emtricitabine Pharmacokinetics Before and After Reducing Ritonavir Boosting of a Fosamprenavir/Tenofovir/Emtricitabine Regimen from 200 mg to 100 mg Once Daily (TELEX II). [Journal Article]
HIV Clin Trials 2009 May-Jun; 10(3):160-7.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19632952/full_citation/Occurrence_of_Selective_Ritonavir_Nonadherence_and_Dose_Staggering_in_Recipients_of_Boosted_HIV_1_Protease_Inhibitor_Therapy_Shuter J, Sarlo JA, Rode RA, et al. 
Occurrence of Selective Ritonavir Nonadherence and Dose-Staggering in Recipients of Boosted HIV-1 Protease Inhibitor Therapy. [Journal Article]
HIV Clin Trials 2009 May-Jun; 10(3):135-42.
Abstract | Full Citation